NAMS
NewAmsterdam Pharma Company N.V.NASDAQHealthcare$32.99+0.55%ClosedMarket Cap: $3.79B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
5.71
P/S
174.33
EV/EBITDA
-14.17
DCF Value
$3.47
FCF Yield
-3.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.7%
Operating Margin
-1002.9%
Net Margin
-905.7%
ROE
-27.5%
ROA
-26.5%
ROIC
-33.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $32.0K | -84.4% | $-66.0M | $-74.9M | $-0.65 | — |
| FY 2025 | $22.5M | 99.7% | $-225.7M | $-203.8M | $-1.75 | — |
| Q3 2025 | $348.0K | 100.0% | $-55.1M | $-72.0M | $-0.61 | — |
| Q2 2025 | $19.1M | 100.0% | $-35.6M | $-17.4M | $-0.15 | — |
| Q1 2025 | $3.0M | 100.0% | $-68.9M | $-39.5M | $-0.34 | — |
| Q4 2024 | $12.8M | 100.0% | $-43.2M | $-92.2M | $-0.98 | — |
| FY 2024 | $45.6M | 100.0% | $-176.3M | $-241.6M | $-2.56 | — |
| Q3 2024 | $29.1M | 100.0% | $-25.0M | $-16.6M | $-0.18 | — |
| Q2 2024 | $2.3M | 100.0% | $-52.6M | $-39.0M | $-0.41 | — |
| Q1 2024 | $1.4M | 100.0% | $-55.5M | $-93.8M | $-1.06 | — |
| Q4 2023 | $803.0K | 100.0% | $-51.1M | $-49.5M | $-0.52 | — |
| FY 2023 | $14.1M | 100.0% | $-183.0M | $-176.9M | $-2.15 | — |